Advertisement

Abstract

Freund’s adjuvant (mycobacterial cells in a water-in-oil emulsion containing the antigen in the water phase) (18) is used for stimulating the production of antibodies against the antigen used. A five to ten fold titer of antibodies is obtained with complete Freund’s adjuvant in comparison with incomplete adjuvant lacking Mycobacteria. It also induces delayed hypersensitivity to the antigen (9, 72).

Keywords

Mycolic Acid Benzyl Ester Adjuvant Activity Muramyl Dipeptide Muramic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Abbreviations

Mur

muramic acid

DAP

diaminopimelic acid

Ac

acetyl

Boc

Tert butyloxycarbonyl

Z

Benzyloxycarbonyl

For

Formyl

Bzl

benzyl

Me

methyl

Ts

tosyl

Ms

mesyl

NBzl

nitrobenzyl

OSu

succinimide ester

DMF

dimethylformamide

AcOH

acetic acid

MDP

muramyl dipeptide (Nacetyl-muramyl-L-alanyl-D-isoglutamine)

WSA

Water Soluble Adjuvant

AL

multi-poly-D, L-alanyl-poly-L-lysine

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adam, A, M. Devys, V. Souvannavong, P. Lefrancier, and E. Lederer: Correlation of structure and adjuvant activity of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers. Biochem. Biophys. Res. Comm. 72, 339 (1976).Google Scholar
  2. 2.
    Adam, A., J.-F. Petit, J. Wietzerbin-Falzspan, P. Sinay, D. W. Thomas, and E. Lederer: L’acide N-glycolyl-muramique, constituant des parois de Mycobacterium smegmatis: identification par spectrometrie de masse. FEBS Letters 4, 87 (1969).Google Scholar
  3. 3.
    Adam, A, R. Ciorbaru, J.-F. Petit, and E. Lederer: Isolation and properties of a macromolecular water-soluble immunoadjuvant fraction from the cell wall of Myco-bacterium smegmatis. Proc. Natl. Acad. Sci. 69, 851 (1972).Google Scholar
  4. 4.
    Adam, A., R. Ciorbaru, J.-F. Petit, E. Lederer, L. Chedid, A. Lamensans, F. Parant, M. Parant, J. P. Rosselet, and F. M. Berger: Preparation and biological properties of watersoluble adjuvant fractions from delipidated cells of Mycobacterium smegmatis and Nocardia opaca. Infection and Immunity 7, 855 (1973).Google Scholar
  5. 5.
    Arendt, A., A. Kolodziejezyk, and T. Sokolowska: Synthesis of mucopeptide fragments of bacterial cell walls containing diaminopimelic acid. Part IX. Synthesis of pentapeptide related to bacterial mureine fragment. Roczniki Chem. Ann. Soc. Chim. Polonorum. 48, 1921 (1974).Google Scholar
  6. 6.
    Beyerman, H. C., E. W. B. De Leer, and J. Floor: On the repetitive excess mixed anhydride method for the synthesis of peptides. Synthesis of the sequence 1–10 of human growth hormone. Rec. Trav. Chim. Pays.. Bas. 92, 481 (1973).Google Scholar
  7. 7.
    Bricas, E: Survey of the Synthetic Work in the field of the bacterial Cell Wall Peptides. In The Chemistry of Polypeptides (P. G. Katsoyannis, Ed.), p. 205. New York: Plenum Press. 1973.Google Scholar
  8. 8.
    Chaturvedi, N. C., M. C. Khosla, and N. Anand: Synthesis of analogs of bacterial cell wall glycopeptides. J. Med. Chem. 9, 971 (1966).Google Scholar
  9. 9.
    Cheung, S. T, and N. L. Benoiton: N-methylaminoacids in peptide synthesis. The synthesis of N-tert-butyloxycarbonyl-N-methylamino acids by N-methylation. Can. J. Chem. 55, 906 (1977).Google Scholar
  10. 10.
    Das. B. C. and E. Lederer: Mass spectrometry of peptide derivatives: Scope and Limitations. In Peptides 1971 (H. Nesvabda, Ed.), p. 253. Amsterdam: North Holland Publishing Co. 1973.Google Scholar
  11. 11.
    Das, B. C, and E. Nebelin: Structural Characterization of N-acetyl-muramyl-peptides by mass spectrometry. In Peptides 1978 (I. Z. Siemon and G. Kupryszewski, Eds).Google Scholar
  12. 12.
    Defaye, J, and E. Lederer: Synthèse d’un oc-monomycolate de glycerol. Bull. Soc. Chim. Biol. 38, 1301 (1956).Google Scholar
  13. 13.
    Deslauriers, R, and I. C. P. Smith: Conformation and Structure of Peptides, Chapter 1 in: Topics in Carbon-13 N.M.R. Spectroscopy (G. C. Levy, Ed.), Vol. 2. New York, N. Y.: Wiley-Interscience. 1976.Google Scholar
  14. 14.
    Deslauriers, R., I. C. P. Smith, and R. Walter: Conformational flexibility of the Neurohypophyseal Hormones oxytocin and Lysine-Vasopressin. A Carbon-13-Spin- Lattice Relaxation Study of back-bone and side chain. J. Amer. Chem. Soc. 96, 2289 (1974).Google Scholar
  15. 15.
    Durette, P. L., A. Rosegay, M. A. R. Walsh, and T. Y. Shen: Synthesis of (6-3H)- N-acetylmuramyl-L-alanyl-D-isoglutamine. Tetrahedron Lett. 291 (1979).Google Scholar
  16. 16.
    Ellouz, F., A. Adam, R. Ciorbaru, and E. Lederer: Minimal structural requirements for adjuvant activity pf bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Comm. 59, 1317 (1974).Google Scholar
  17. 17.
    Flowers, H. M, and R. W. Jeanloz: The synthesis of 2-acetamido-3-0-(D-l-car- boxyethyl)-2-deoxy-A-D-glucose (N-acetylmuramic acid) and of benzyl glycoside derivatives of 2-amino-3-0-(D-l-carboxy-ethyl)-2-deoxy-D-glucose (Muramic acid). J. Org. Chem. 28, 2983 (1963).Google Scholar
  18. 18.
    Freund, J.: The mode of action of immunologic adjuvants. Advances in Tuberculology 7, 130 (1956).Google Scholar
  19. 19.
    Fujino, M, and C. Hatanaka: A new procedure for the pentachlorophenylation of N-protected amino-acids. Chem. Pharm. Bull. 16, 929 (1968).Google Scholar
  20. 20.
    Hasegawa, A., Y. Kaneda, M. Amano, M. Kiso, and I. Azuma: A facile Synthesis of N-acetyl-muramyl-L-alanyl-D-isoglutamine and its Carbohydrate Analogs and their Immunoadjuvant Activities. Agric. Biol. Chem. 42, 2187 (1978).Google Scholar
  21. 21.
    Hiu, I. J: Water-soluble and lipid-free fraction from BCG, with adjuvant and antitumor activity. Nature New Biology 238, 241 (1972).Google Scholar
  22. 22.
    Howarth, O. W, and D. M. J. Lilley: Carbon-13-NMR of peptides and proteins. Prog. NMR Spectroscopy 12, 1 (1978).Google Scholar
  23. 23.
    Hunter, M. J, and M. L. Ludwig: Amidination. Methods in Enzymol. 25, 585 (1972).Google Scholar
  24. 24.
    Inch, T. D., and H. G. Fletcher, JR.: Synthesis with partially benzylated sugars. VI. Some solvolytic reactions of 2-acetamido-l-0-acyl-2-deoxy-D-glucopyranose and D- galactopyranose derivatives. J. Org. Chem. 31, 1810 (1965).Google Scholar
  25. 25.
    Jeanloz, R. W., E. Walker, and P. Sinay: Synthesis of various glycosides of 2-amino- 3-0-(D-l-carboxyethyl)-2-deoxy-D-glucopyranose (Muramic acid). Carbohyd. Res. 6, 184 (1968).Google Scholar
  26. 26.
    Jolles, P., and A. Paraf: Chemical and Biological Basis of Adjuvants. Molecular Biology, Biophysics, Vol. 13, p. 153. Berlin-Heidelberg-New York: Springer. 1973.Google Scholar
  27. 27.
    Keim, P., R. A. Vigna, R. C. Marshall, and F. R. N. Gurd: Carbon 13-Nuclear Magnetic Resonance of Pentapeptides of glycine containing central residues of aliphatic amino acids. J. Biol. Chem. 248, 6104 (1973).Google Scholar
  28. 28.
    Keim, P., R. A. Vigna, J. S. Morrow, R. C. Marshall, and F. R. N. Gurd: Carbon 13-Nuclear Magnetic Resonance of pentapeptides of glycine containing central residues of Serine, Threonine, Aspartic and Glutamic Acids, Asparagine and Glutamine. J. Biol. Chem. 248, 7811 (1973).Google Scholar
  29. 29.
    Kotani, S., Y. Watanabe, T. Shimono, K. Kato, F. Kinoshita, T. Shiba, S. Kusumoto, Y. Tarumi, K. Yokogawa, and S. Kawata: Abstr. Symp. Intern. Immunostimulants Bacteriens. Pasteur Institute, Paris (1974).Google Scholar
  30. 30.
    Kotani, S., Y. Watanabe, F. Kinoshita, T. Shimono, I. Marisaki, T. Shiba, S. Kusumoto, Y. Tarumi, and K. Ikenaka: Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or aminoacids. Biken J. 18, 105 (1975).Google Scholar
  31. 31.
    Kotani, S: Biological activities of bacterial cell wall peptidoglycans and their sub- units, with special reference to the immuno-adjuvant actions. Seikagaku 48, 1081 (1976).Google Scholar
  32. 32.
    Kotani, S., F. Kinoshita, Y. Watanabe, J. Morisaki, T. Shimono, K. Kato, T. Shiba, S. Kusumoto, K. Ikenaka, and Y. Tarumi: Effects of Chemical modifications of the glutamic acid residue in N-acetyl-muramyl-peptides on the immunoadjuvancies of the molecules. Biken J. 20, 125 (1977).Google Scholar
  33. 33.
    Kusumoto, S., Y. Tarumi, K. Ikenaka, and T. Shiba: Chemical synthesis of N- acetylmuramyl-peptides with partial structures of bacterial cell wall and their analogs in relation to immunoadjuvant activities. Bull. Chem. Soc. Japan 49, 533 (1976).Google Scholar
  34. 34.
    Kusumoto. S.. S. Okada. and T. Shiba: Synthesis of 6-O-mycoloyl-N-acetyl-muramyl- L-alanyl-D-isoglutamine with immunoadjuvant activity. Tetrahedron Lett. 4287 (1976).Google Scholar
  35. 35.
    Kusumoto, S., K. Ikenaka, and T. Shiba: Synthesis of N-acetylmuramyl-L-(U-14C-)- alanyl-D-isoglutamine. Tetrahedron Letters 4055 (1977).Google Scholar
  36. 36.
    Kusumoto, S., S. Okada, K. Yamamoto, and T. Shiba: Synthesis of 6-O-acyl- derivatives of immunoadjuvant active N-acetyl-muramyl-L-alanyl-D-isoglutamine. Bull. Chem. Soc. Japan. 51, 2122 (1978).Google Scholar
  37. 37.
    Kusumoto, S., M. Inage, T. Shiba, I. Azuma, and Y. Yamamura: Synthesis of long chain fatty acid esters of N-acetyl-muramyl-L-alanyl-D-isoglutamine in relation to anti-tumor activity. Tetrahedron Lett. 4895 (1978).Google Scholar
  38. 38.
    Kusumoto, S., K. Yamamoto, and T. Shiba: Synthesis of N-acetyl-p-D-glucosaminyl- (1 4)-N-acetyl-muramyl-L-alanyl-D-isoglutamine. Tetrahedron Lett. 4407 (1978).Google Scholar
  39. 39.
    Lanzilotti, A. E., E. Benz, and L. Goldman: Total Syntheses of N3-l-(2-acetamido- 3-D-glueosyl)-D-propionyl-L-alanyl-D-cx- and y-glutamyl-L-lysyl-D-alanyl-D-ala- nine. and identity of the y-glutamyl isomer with the glycopeptide of a bacterial cell wall precursor. J. Amer. Chem. Soc. 86, 1880 (1964).Google Scholar
  40. 40.
    Lederer, E.: The mycobacterial cell wall. Pure and Applied Chemistry 25, 135 (1971).Google Scholar
  41. 41.
    Lederer, E., A. Adam, R. Ciorbaru, J.-F. Petit, and J. Wietzerbin: Cell walls of my co-bacteria and related organisms; chemistry and immunostimulant properties. Molecular and Cellular Biochemistry 7, 87 (1975).Google Scholar
  42. 42.
    Lederer, E: Natural and synthetic immunostimulants related to the mycobacterial cell wall. Medicinal Chemistry V, p. 257. Amsterdam: Elsevier Scientific Publishing Company. 1977.Google Scholar
  43. 43.
    Lefrancier, P., and E. Bricas: Synthèse de la subunité peptidique du peptidoglycane de la paroi de trois bactéries gram-positif et de peptides de structure analogue. Bull. Soc. Chim. Biol. 49, 1257 (1967).Google Scholar
  44. 44.
    Lefrancier, P., J. Choay, M. Derrien, and I. Lederman: Synthesis of N-acetyl- muramyl-L-alanyl-D-isoglutamine, an adjuvant of the immune response and of some N-acetyl-muramyl-peptide analogs. Int. J. Peptide Protein Res. 9, 249 (1977).Google Scholar
  45. 45.
    Lefrancier, P., M. Derrien, I. Lederman, F. Nief, J. Choay, and E. Lederer: Synthesis of some new analogs of the immunoadjuvant glycopeptide MDP (N-acetyl- muramyl-L-alanyl-D-isoglutamine). Int. J. Peptide Res. 11, 289 (1978).Google Scholar
  46. 46.
    Lefrancier, P., M. Petitou, M. Level, M. Derrien, J. Choay, and E. Lederer, Synthesis of N-acetyl-muramyl-L-alanyl-D-glutamic a-amide (MDP) or a-methyl ester derivatives, bearing a lipophilic group at the C-terminal peptide end. Int. J. Peptide Protein Res. 14, 437 (1979).Google Scholar
  47. 47.
    Lefrancier P etal., unpublished results.Google Scholar
  48. 48.
    Lubin, B., V. Pena, W. C. Mentzer, E. Bymum, T. B. Bradley, and L. Packer: Dimethyl Adipimidate: A new Antisickling Agent. Proc. Natl. Acad. Sei. USA. 72, 43 (1975).Google Scholar
  49. 49.
    Merser, C., and P. Sinay: Abstr. Symp. Intern. Immunostimulants. Bacteriens. Pasteur Institute, Paris, 1974.Google Scholar
  50. 50.
    Merser, C., P. Sinay, and A. Adam: Total Synthesis and adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Comm. 66, 1316 (1975).Google Scholar
  51. 51.
    Merser, C: Synthèse totale du disaccharide de base et de divers fragments du peptidoglycane des parois bactériennes. Activité immunoadjuvante d’un muramyl dipeptide. Thèse de Sciences, Orléans, 1975.Google Scholar
  52. 52.
    Migliore, D., and P. Jolles: A hydrosoluble adjuvant active mycobacterial “poly- saccharide-peptidoglycan”. Preparation by a simple extraction technique of the bacterial cells (strain Peurois). FEBS Letters 25, 301 (1972).Google Scholar
  53. 52a.
    Nebelin, E., and B. C. Das: Mass spectrometry of Synthetic Glycopeptide analogs of Bacterial Peptidoglycans (MDP and Derivatives) FEBS Letters 107, 254 (1979).Google Scholar
  54. 53.
    Osawa, T., and R. W. Jeanloz: An improved, stereoselective synthesis of 2-amino- 3-0-(D-l-carboxyethyl)-2-deoxy-D-glucose (Muramic acid). J. Org. Chem. 30, 448 (1965).Google Scholar
  55. 54.
    Parant, M., C. Damais, F. Audibert, F. Parant, L. Chedid, E. Sache, P. Lefrancier, J. Choay, and E. Lederer: In vivo and in vitro stimulation of non specific immunity by the ß-D-p-amino-phenyl glycoside of N-acetyl-muramyl-L-alanyl-D-isoglutamine and an oligomer prepared by cross-linking with glutaraldehyde. J. Infec. Dis. 138, 378 (1978).Google Scholar
  56. 55.
    Parant, M., F. Parant, L. Chedid, A. Yapo, J. F. Petit, and E. Lederer: Fate of 14C-Labeled muramyl-dipeptide, a synthetic immunoadjuvant, after administration to the mouse. Int. J. Immunopharmacol., 1, 35 (1979).Google Scholar
  57. 56.
    Petit, J. F: person, comm.Google Scholar
  58. 57.
    Pichat, L., J. Tostain, P. Lefrancier, P. Sinay. and E. Lederer: Synthèse de la N-acetylmuramyl (oxo-14C-Propyl)-L-alanyl-D-isoglutamine. [“Muramyl (oxo-14C- Propyl) dipeptide”: (MDP-14C) J. of labelled compounds and radiopharmaceuticals 17, 153 (1980).Google Scholar
  59. 58.
    Polonsky, J., E. Soler, and J. Varenne: Sur la synthèse du cord-factor et de ses analogues. Carbohyd. Res. 65, 295 (1978).Google Scholar
  60. 59.
    Qureschi, N., and K. Takayama: Characterization of the Purified Components of a new homologous series of a Mycolic Acids from Mycobacterium tuberculosis. H 37 Ra. J. Biol. Chem. 253, 5411 (1978).Google Scholar
  61. 60.
    Raju, M. S., T. D. J. Halls, E. Wenkert, M. Zuber, P. Lefrancier, and E. Lederer: Anomeric configuration of the immunostimulant muramyl dipeptide MDP and some of its derivatives. Carbohyd. Res. 81, 173 (1980).Google Scholar
  62. 61.
    Reichert, C. M., C. Carreli, M. Jolivet, F. Audibert, P. Lefrancier, and L. Chedid: Synthesis of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) containing conjugates and their use as a hapten-carrier system Mol. Immunol. 17, 357 (1980).Google Scholar
  63. 62.
    Saito, H., and I. C. P. Smith: Carbon-13 Nuclear Magnetic Resonance Studies of poly- amino acids: The Helix-Coil Transition of Poly-Lysine. Arch. Biochem. Biophys. 158, 154 (1973).Google Scholar
  64. 63.
    Schleifer, K. H., and O. Kandler: Peptidoglycan types of bacterial Cell Walls and their taxonomic implications. Bacteriol. Rev. 36, 407 (1972).Google Scholar
  65. 64.
    Sela, M., E. Katchalski, and M. Gehatia: Multichain Polyaminoacids. J. Amer. Chem. Soc. 78, 746 (1956).Google Scholar
  66. 65.
    Sharon, N., and S. Seifter: A transglycosylation reaction catalyzed by lysozyme. J. Biol. Chem. 239, P. C. 2398 (1964).Google Scholar
  67. 66.
    Shiba, T., S. Okada, S. Kusumoto, I. Azuma, and Y. Yamamura: Synthesis of 6-0- mycoloyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with antitumor activity. Bull. Chem. Soc. Japan 51, 3307 (1978).Google Scholar
  68. 67.
    Sinay, P: person, comm.Google Scholar
  69. 68.
    Vilkas, E., and E. Lederer: N-méthylation de peptides par la méthode de Hakomori: Structure du mycoside Cb 1. Tetrahedron Lett. 3089 (1968).Google Scholar
  70. 69.
    Walker, T. E., R. E. London, T. W. Whaley, R. Barker, and N. A. Matwiyoff: Carbon-13 Nuclear Magnetic Resonance Spectroscopy of (1-13C) Enriched monosaccharides. Signal Assignments and orientation dépendance of geminal and vicinal Carbon- Carbon and Carbon-Hydrogen Spin-Spin coupling constants. J. Amer. Chem. Soc. 98, 5807 (1976) and references cited therein.Google Scholar
  71. 70.
    Wang, S. S., B. F. Gisin, D. P. Winter, R. Makofske, I. D. Kulesha, C. Tzougraki, and J. Meienhofer: Facile Synthesis of Amino Acid and Peptide Esters under mild conditions via Caesium salts. J. Org. Chem. 42, 1286 (1977).Google Scholar
  72. 71.
    White, R. G., L. Bernstock, R. G. S. Johns, and E. Lederer: The influence of components of Mycobacterium tuberculosis and other mycobacteria upon antibody production to ovalbumin. Immunology 1, 54 (1958).Google Scholar
  73. 72.
    White, R. G: The adjuvant effect of microbial products on the immune response. Ann. Rev. Microbiol. 30, 579 (1976).Google Scholar
  74. 73.
    Zaoral, M., J. Jezek, R. Straka, and K. Masek: Glycopeptides of Bacterial walls. A novel method of removal of benzyl and benzylidene residues. Coll. Czechoslov. Chem. Commun. 43, 1797 (1978).Google Scholar
  75. 74.
    Zervas, L., and S. Konstas: Uber Glucosaminide. Chem. Ber. 93, 435 (1960).Google Scholar
  76. 75.
    Zurabyan, S. E., T. P. Volosyuk, and A. J. Khorlin: Oxazoline synthesis of 1-2- iras-2-acetamido-2-deoxyglycosides. Carbohyd. Res. 9, 215 (1969).Google Scholar

References of Addendum

  1. 76.
    Dukor, P., L. Tarcsay, and G. Baschang: Annu. Rep. Med. Chem. 14, 146 (1979).Google Scholar
  2. 77.
    Lefrancier, P: First international Conference on Immunopharmacology (1980) Brighton (U.K.).Google Scholar
  3. 78.
    Hasegawa, A., H. Okumura, M. Kiso, I. Azuma, and Y. Yamamura: Carbohydr. Res. 79, C. 20 (1980).Google Scholar
  4. 79.
    Kiso, M., Y. Kaneda, H. Okumura, A. Hasegawa, I. Azuma, and Y. Yamamura: Carbohydr. Res 79, C. 17 (1980).Google Scholar
  5. 80.
    Hasegawa, A., H. Okumura, M. Kiso, I. Azuma, and Y. Yamamura: Agrie. Biol. Chem. 44, 1301 (1980).Google Scholar
  6. 81.
    Hasegawa, A., H. Okumura, M. Kiso, I. Azuma, and Y. Yamamura: Agrie Biol. Chem. 44, 1309 (1980).Google Scholar
  7. 82.
    Durette, P. L., E. P. Meitzner, and T. Y. Shen: Carbohydr. Res. 77, C. 1 (1979).Google Scholar
  8. 83.
    Tsujimoto, M., F. Kinoshita, T. Okunaga, S. Kotani, S. Kusumoto, K. Yamamoto, and T. Shiba: Microbiol. Immunol. 23, 933 (1979).Google Scholar
  9. 84.
    Kiso, M., Y. Kaneda, R. Shimizu, and A. Hasegawa: Carbohydr. Res. 86, C. 8 (1980).Google Scholar
  10. 85.
    Ivanov, V. T.: 16th European Peptide Symposium 1980. Helsingor (DK).Google Scholar
  11. 86.
    Durette, P. L., E. P. Meitzner, and T. Y. Shen: Tetrahedron Lett. 42, 4013 (1979).Google Scholar
  12. 87.
    Kobayashi, S., T. Fukuda, I. Imada, M. Fujino, I. Azuma, and Y. Yamamura: Chem. Pharm. Bull. 27, 3193 (1979).Google Scholar
  13. 88.
    Azuma, I., M. Yamawaki, M. Uemiya, I. Saiki, Y. Tanio, S. Kobayadhi, T. Fukuda, I. Imada, and Y. Yamamura: Gann. 70, 847 (1980).Google Scholar
  14. 89.
    Uemiya, M., I. Saiki, T. Kusama, I. Azuma, and Y, Yamamura: Microbiol. Immunol. 23, 821 (1979).Google Scholar
  15. 90.
    Masek, K., M. Zaoral, J. Jezek, and V. Krchnak: Experientia 35, 1397 (1979).Google Scholar
  16. 91.
    Migliore-Samour, D., J. Bouchaudon, F. Floch, A. Zerial, L. Ninet, G. H. Werner, and P. Jolles: C. R. Acad. Sci. Paris 289, 473 (1979).Google Scholar
  17. 92.
    Migliore-Samour, D., J. Bouchaudon, F. Floch, A. Zerial, L. Ninet, G. H. Werner, and P. Jolles: Life Sciences 26, 883 (1980).Google Scholar
  18. 93.
    Parant, M.: Springer Semin. Immunopathol. 2, 101 (1979).Google Scholar
  19. 94.
    Lederer, E.: J. Med. Chem. 23, 819 (1980).Google Scholar

Appendix

  1. Johnson, A. G., F. Audibert, and L. Chedid: Synthetic immunoregulating molecules: a potential bridge between chemotherapy and immunotherapy of cancer. Cancer Immunol. Immunother. 3, 219 (1978).Google Scholar
  2. Chedid, L., F. Audibert, and A. G. Johnson: Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Progress in Allergy 25, 63 (1978).Google Scholar
  3. Chedid, L., and E. Lederer: Past, present and future of the synthetic immunoadjuvant MDP and its analogues. Biochemical Pharmacology 27, 2183 (1978).Google Scholar
  4. Parant, M.: Biological properties of a new synthetic adjuvant, muramyl dipeptide (MDP). Springer Seminars in Immunopathology 2, 101 (1979).Google Scholar
  5. Chedid, L., C. Carelli, and F. Audibert: Recent developments concerning a synthetic immunoregulating molecule: muramyl dipeptide. J. Reticuloendothelial Soc. 26S, 631 (1979).Google Scholar

Adjuvant activity

  1. Ellouz, F., A. Adam, R. Ciorbaru, and E. Lederer: Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Comm. 59, 1317 (1974).Google Scholar
  2. Kotani, S., Y. Watanabe, F. Kinoshita, T. Shimono, I. Morisaki, T. Shiba, S. Kusumoto, Y. Tarumi, and K. Ikenaka: Immunoadjuvant activities of synthetic N-acetyl-muramyl- peptides or -amino acids. Biken J. 18, 105 (1975).Google Scholar
  3. Azuma, I., K. Sugimura, T. Taniyama, M. Yamawaki, Y. Yamamura, S. Kusumoto, S. Okada, and T. Shiba: Adjuvant activity of mycobacterial fractions: immunological properties of synthetic N-acetyl-muramyl dipeptide and the related compounds. Infect. Immun. 14, 18 (1976).Google Scholar
  4. Audibert, F., L. Chedid, J. Lefrancier, and J. Choay: Distinctive adjuvanticity of synthetic analogs of mycobacterial water-soluble components. Cell. Immunol. 21, 243 (1976).Google Scholar
  5. Tanaka, A., R. Saito, K. Sugiyama, I. Morisaki, S. Kotani, S. Kusumoto, and T. Shiba: Adjuvant activity of synthetic N-acetyl-muramyl peptides in rats. Infect. Immun. 15, 332 (1977).Google Scholar
  6. Audibert, F., L. Chedid, P. Lefrancier, J. Choay, and E. Lederer: Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl- muramyl-L-alanyl-D-isoglutamine (MDP). Ann. Immunol.. (Inst. Pasteur) 128C, 653 (1977).Google Scholar
  7. Kotani, S., F. Kinoshita, I. Morisaki, T. Shimono, T. Okunaga, H. Takada, M. Tsuji- Moto, Y. Watanabe, K. Kato, T. Shiba, S. Kusumoto, and S. Okada: Immunoadjuvant activities of synthetic 6-O-acyl-N-acetyl-muramyl-L-alanyl-D-isoglutamine with special reference to the effect of its administration with liposomes. Biken J. 20, 95 (1977).Google Scholar
  8. Souvannavong, V., A. Adam, and E. Lederer: Kinetics of the humoral and cellular immune response of guinea pigs after injection of the synthetic adjuvant N-acetyl- muramyl-L-alanyl-D-isoglutamine: comparison with Freund complete adjuvant. Infect. Immun. 19, 966 (1978).Google Scholar
  9. Azuma, I., K. Sugimura, M. Yamawaki, M. Uemiya, S. Kusumoto, S. Okada, T. Shiba, and Y. Yamamura: Adjuvant activity of synthetic 6-0-mycoloyl-N-acetyl-muramyl- L-alanyl-D-isoglutamine and related compounds. Infect. Immun. 20, 600 (1978).Google Scholar
  10. Masek, K., M. Zaoral, J. Jezek, and R. Straka: Immunoadjuvant activity of synthetic N-acetyl-muramyl-dipeptide. Experientia 34, 1363 (1978).Google Scholar
  11. Heymer, B., H. Finger, and C. H. WIRSING: Immunoadjuvant effects of the synthetic muramyl dipeptide (MDP) N-acetylmuramyl-L-alanyl-D-isoglutamine. Zeit.-Immuni- tatforsch. 155, 87 (1978).Google Scholar
  12. Souvannavong, V., and A. Adam: Opposite effects of the synthetic adjuvant N-acetyl- muramyl-L-alanyl-D-isoglutamine on the immune response in mice depending on experimental conditions. Eur. J. Immunol. 10, 654 (1980).Google Scholar
  13. Azuma, I., K. Kamisango, I. Saiki, Y. Tanio, S. Kobayashi, and Y. Yamamura: Adjuvant activity of N-acetyl-muramyl dipeptides for the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs. Infect. Immun. 29, 1193 (1980).Google Scholar

Biological activity of diastereoisomers

  1. Adam, A., M. Devys, V. Souvannavong, P. Lefrancier, J. Choay, and E. Lederer: Correlation of structure and adjuvant activity of N-acetyl-muramyl-L-alanyl-D-iso- glutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers. Biochem. Biophys. Res. Comm. 72, 339 (1976).Google Scholar
  2. Chedid, L., F. Audibert, P. Lefrancier, J. Choay, and E. Lederer: Modulation of the immune response by a synthetic adjuvant and analogs. Proc. Natl. Acad. Sci. 73, 2472 (1976).Google Scholar
  3. Kotani, S., Y. Watanabe, F. Kinoshita, I. Morisaki, K. Kato, T. Shiba, S. Kusumoto, Y. Tarumi, and K. Ikenaka: The effect of replacement of L-alanine residue by glycine, L-serine or D-alanine in an N-acetyl muramyl-L- alanyl-D-isoglutamine on immunoadjuvanticities of molecules. Biken J. 20, 39 (1977).Google Scholar
  4. Chedid, L., M. Parant, F. Parant, F. Audibert, P. Lefrancier, J. Choay, and M. SELA: Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly-(DL-alanyl)-poly-(L-lysine) carrier. Proc. Natl. Acad. Sci. USA 76, 6557 (1979).Google Scholar
  5. Audibert, F., M. Parant, C. Damais, P. Lefrancier, M. Derrien, J. Choay, and L. Chedid: Dissociation of immunostimulant activities of muramyl dipeptide (MDP) by linking amino-acids or peptides to the glutaminyl residue. Biochem. Biophys. Res. Comm. 96, 915 (1980).Google Scholar

Stimulation of non-specific resistance

  1. Chedid, L., M. Parant, F. Parant, P. Lefrancier, J. Choay, and E. Lederer: Enhancement of non-specific immunity to Klebsiella pneumoniae infection by a synthetic immuno- adjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine) and several analogs. Proc. Natl. Acad. Sci. 74, 2089 (1977).Google Scholar
  2. Damais, C., M. Parant, and L. Chedid: Non-specific activation of murine spleen cells in vitro by a synthetic immunoadjuvant (N-acetyl-muramyl-L-alanyl-D-isoglutamine). Cell Immunol. 34, 49 (1977).Google Scholar
  3. Yamamura, Y., I. Azuma, K. Sugimura, M. Yamawaki, M. Uemiya, S. Kusumoto, S. Okada, and T. Shiba: Immunological and antitumor activities of synthetic 6-O-mycoloyl- N-acetylmuramyl dipeptides. Proc. Japan Acad. 53, 63 (1977).Google Scholar
  4. Parant, M., F. Parant, and L. Chedid: Enhancement of the neonate’s non-specific immunity to Klebsiella infection by muramyl dipeptide, a synthetic immunoadjuvant. Proc. Natl. Acad. Sci. 75, 3395 (1978).Google Scholar
  5. Parant, M., C. Damais, F. Audibert, F. Parant, L. Chedid, E. Sache, P. Lefrancier, J. Choay, and E. Lederer: In vivo and in vitro stimulation of non-specific immunity by the P-D-p-aminophenyl glycoside of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP) and an oligomer prepared by cross linking with glutaraldehyde. J. Infect. Dis. 138, 378 (1978).Google Scholar
  6. Kierszenbaum, F., and R. W. Ferraresi: Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect. Immun. 25, 273 (1979).Google Scholar
  7. Taniyama, T., and H. T. Holden: Direct augmentation of cytolytic activity to tumor- derived macrophages and macrophage cell lines by muramyl dipeptide. Cellular Immunology 48, 369 (1979).Google Scholar
  8. Mclaughlin, C. A., S. M. Schwartzman, B. L. Horner, G. H. Jones, J. G. Moffatt, J. J. Nestor JR, and D. Tegg: Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. Science 208, 415 (1980).Google Scholar
  9. Matthews, T. R, and E. B. Fraser-Smith: Protective effect of muramyl dipeptide and analogs against Pseudomonas aeruginosa and Candida albicans infections of mice. Curr. Chemother. Infect. Diseases, Proc. Int. Cong. Chemother. 11th 1979, 2, 1734 (1980).Google Scholar

Induction of auto-immune diseases

  1. Nagai, Y: Modulation of the immunologic response of myelin basic protein by extrinsic and intrinsic factors. Neurology 26, 45 (1976).Google Scholar
  2. Toullet, F., F. Audibert, G. A. Voisin, and L. Chedid: Production d’une orchiépididymite aspermatogénétique auto-immune chez le cobaye, à l’aide de différents adjuvants hydro- solubles. Ann. Immunol. (Inst. Pasteur) 128 C, 267 (1977).Google Scholar
  3. Nagai, Y., K. Akiyama, K. Suzuki, S. Kotani, Y. Watanabe, T. Shimono, T. Shiba, K. Kusumoto, F. Ikuta, and S. Takeda: Minimum structural requirements for encephalitogen and for adjuvant in the induction of experimental allergie encephalomyelitis. Cell. Immunol. 35, 158 (1978).Google Scholar
  4. Nagai, Y., K. Akiyama, S. Kotani, Y. Watanabe, T. Shimono, T. Shiba, and S. Kusumoto: Structural specificity of synthetic peptide adjuvant for induction of experimental allergic encephalomyelitis. Cell. Immunol. 35, 168 (1978).Google Scholar
  5. De Kozak, Y., F. Audibert, B. Thillaye, L. Chedid, and J. P. Faure: Effets d’adjuvants hydrosolubles d’origine mycobactérienne sur l’induction et la prévention de l’uvéo-rétinite autoimmune expérimentale chez le cobaye. Ann. Immunol. (Inst. Pasteur) 130 C, 29 (1979).Google Scholar
  6. Lowy, I., C. Leclerc, and L. Chedid: Induction of antibodies directed against self and altered-self determinants by a synthetic adjuvant, muramyl dipeptide and some of its derivatives. Immunology 39, 441 (1980).Google Scholar
  7. Nagao, S., and A. Tanaka: Muramyl dipeptide-induced adjuvant arthritis. Infect. Immun. 28, 624 (1980).Google Scholar

Mechanism of action

  1. Juy, D., and L. Chedid: Comparison between macrophage activation and enhancement of non-specific resistance to tumors by mycobacterial immunoadjuvants. Proc. Natl. Acad. Sci. 72, 4105 (1975)Google Scholar
  2. Lowy, I., C. Bona, and L. Chedid: Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell. Immunol. 29, 195 (1977).Google Scholar
  3. Specter, S., H. Friedman, and L. Chedid: Dissociation between the adjuvant versus mitogenic activity of a synthetic muramyl dipeptide for murine splenocytes. Proc. Soc. Exp. Biol. Med. 155, 349 (1977).Google Scholar
  4. Takada, H., S. Kotani, S. Kusumoto, Y. Tarumi, K. Ikenaka, and T. Shiba: Mitogenic activity of adjuvant-active N-acetyl-muramyl-L-alanyl-D-isoglutamine and its analogues. Biken J. 20, 81 (1977).Google Scholar
  5. Tanaka, A., S. Nagao, R. Saito, S. Kotani, S. Kusumoto, and T. Shiba: Correlation of stereochemistry specific structure in muramyl dipeptide between macrophage activation and adjuvant activity. Biochem. Biophys. Res. Comm. 77, 621 (1977).Google Scholar
  6. Damais, C., M. Parant, L. Chedid, P. Lefrancier, and J. Choay: In vitro spleen cell responsiveness to various analogs of MDP(N-acétyl-muramyl-L-alanyl-D-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice. Cell. Immunol. 35, 173 (1978).Google Scholar
  7. Sugimoto, M., R. N. Germain, L. Chedid, and B. Benacerraf: Enhancement of carrier- synthetic helper T-cell function by the synthetic adjuvant, N-acetyl-muramyl-L-alanyl- D-isoglutamine (MDP). J. Immunol. 120, 980 (1978).Google Scholar
  8. Yamamoto, Y., S. Nagao, A. Tanaka, T. Koga, and K. Onoue: Inhibition of macrophage migration by synthetic muramyl dipeptide. Biochem. Biophys. Res. Comm. 80, 923 (1978).Google Scholar
  9. Damais, C., M. Parant, and L. Chedid In vitro responsiveness of immunocytes to a synthetic immunoadjuvant, muramyl dipeptide, and different synthetic analogs. Antibiotics Chemother. 24, 19 (1978).]Google Scholar
  10. Emori, K., and A. Tanaka: Granuloma formation by synthetic bacterial cell wall fragment: muramyl dipeptide. Infect. Immun. 19, 613 (1978).Google Scholar
  11. Leclerc, C., I. Lowy, and L. Chedid: Influence of MDP and of some analogous synthetic glycopeptides on the in vitro mouse spleen cell viability and immune response to sheep erythrocytes. Cell. Immunol. 38, 286 (1978).Google Scholar
  12. Fevrier, M., J. L. Birrien, C. Leclerc, L. Chedid, and P. Liacopoulos: The macrophage, target cell of the synthetic adjuvant muramyl dipeptide. Eur. J. Immunol. 8, 558 (1978).Google Scholar
  13. Watson, J., and C. Whitlock: Effect of a synthetic adjuvant on the induction of primary immune responses in T cell-depleted spleen cultures. J. Immunol. 121, 383 (1978).Google Scholar
  14. Leclerc, C., F. Audibert, and L. Chedid: Influence of a synthetic adjuvant (MDP) on qualitative and quantitative changes of serum globulins. Immunology 35, 963 (1978).Google Scholar
  15. Adam, A., V. Souvannavong, and E. Lederer: Non-specific MIF-like activity induced by the synthetic immunoadjuvant: N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP). Biochem. Biophys. Res. Comm. 85, 684 (1978).Google Scholar
  16. Hadden, J. W: Effects of Isoprinosine, Levamisole, Muramyl dipeptide, and SM1213 on lymphocyte and macrophage function in vitro. Cancer Treatment Reports, 62, 1981 (1978).Google Scholar
  17. Pabst, M. J., and R. B. Johnston: Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J. Exp. Med. 151, 101 (1980).Google Scholar
  18. Oppenheim, J. J., A. Togawa, L. Chedid, and S. Mizel: Components of Mycobacteria and muramyl dipeptide with adjuvant activity induce lymphocyte activating factor. Cell. Immunol. 50, 71 (1980).Google Scholar
  19. Tanaka, A., S. Nagao, K. Imai, and R. Mori: Macrophage activation by muramyl dipeptide as measured by macrophage spreading and attachment. Microbiol. Immunol. 24, 547 (1980).Google Scholar
  20. Tenu, J. P., E. Lederer, and J. F. Petit: Stimulation of thymocyte mitogenic protein secretion and of cytostatic activity of mouse peritoneal macrophages by trehalose dimycolate and muramyl dipeptide. Eur. J. Immunol. 10, 647 (1980).Google Scholar

Vaccitation

  1. Audibert, F., L. Chedid, and C. Hannoun: Augmentation de la réponse immunitaire au vaccin grippal par un glycopeptide synthétique adjuvant (N-acétyl-muramyl-L)- alanyl-D-isoglutamine). C. R. Acad. Sei. Paris 285, série D, 467 (1977).Google Scholar
  2. Webster, R. G., W. P. Glezen, C. Hannoun, and W. G. Laver: Potentiation of the immune response to influenza virus subunit vaccines. J. Immunol. 119, 2073 (1977).Google Scholar
  3. Siddiqui, W. A., D. W. Taylor, S. C. Kan, K. Kramer, S. M. Richmond-Crum, S. Kotani, T. Shiba, and S. Kusumoto: Vaccination of experimental monkeys against Plasmodium falciparum: a possible safe adjuvant. Science 201, 1237 (1978).Google Scholar
  4. Reese, R. T., W. Trager, J. B. Jensen, D. A. Miller, and R. Tantravahi: Immunization against malaria with antigen from Plasmodium falciparum cultivated in vitro. Proc. Natl. Acad. Sei. 75, 5665 (197dGoogle Scholar
  5. Mitchell, G. H., W. H. G. Richards, A. Voller, F. M. Dietrich, and P. Dukor: Nor-MDP, saponin, corynebacteria, and pertussis organisms as immunological adjuvants in experimental malaria vaccination of macaques. Bulletin World Health Organization 57, 189 (197dGoogle Scholar
  6. Edelman, R: Vaccine adjuvants. Reviews Infect. Dis. 2, 370 (1980).Google Scholar

Copyright information

© Springer-Verlag/Wien 1981

Authors and Affiliations

  • P. Lefrancier
    • 1
  • E. Lederer
    • 2
    • 3
  1. 1.Institut ChoayMontrougeFrance
  2. 2.Laboratoire de BiochimieC.N.R.S.Gif-sur-YvetteFrance
  3. 3.Institut de BiochimieOrsayFrance

Personalised recommendations